Citing a sharpened focus on neoantigen-directed immunotherapies, Advaxis (ADXS -4.4%) announces that it will terminate its Phase 3 AIM2CERV trial evaluating axalimogene filolisbac (AXAL) in patients with high-risk locally advanced cervical cancer, adding that it will continue to support its clinical development in other HPV-related cancers.
The company also cited the cost ($80M – 90M) and time (at least three years for initial efficacy data) required to complete the study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.